Difference between revisions of "UMODL1-AS1"
| Line 1: | Line 1: | ||
==Annotated Information== | ==Annotated Information== | ||
| + | [[File:LncRNA signature for recurrence based on RNA expression.jpg|right|thumb|400px|'''LncRNA signature for recurrence based on RNA expression'''<ref name="ref1" />]] | ||
| + | [[File:Alterations of lncRNAs associated with ER, PR and HER-2.png|right|thumb|480px|'''Alterations of lncRNAs associated with ER, PR and HER-2'''<ref name="ref1" />]] | ||
===Approved Symbol=== | ===Approved Symbol=== | ||
UMODL1-AS1 （UMODL1 antisense RNA 1） | UMODL1-AS1 （UMODL1 antisense RNA 1） | ||
| − | |||
| − | |||
===Previous Symbols=== | ===Previous Symbols=== | ||
C21orf128 | C21orf128 | ||
Latest revision as of 13:14, 7 January 2018
Contents
Annotated Information
LncRNA signature for recurrence based on RNA expression[1]
Alterations of lncRNAs associated with ER, PR and HER-2[1]
Approved Symbol
UMODL1-AS1 （UMODL1 antisense RNA 1）
Previous Symbols
C21orf128
Synonyms
FLJ33471
Chromosome
21q22.3
RefSeq ID
NR_027243
Disease
breast cancer
Ensembl ID
ENSG00000184385
Function
UMODL1-AS1's upregulation can predict recurrence of breast cancer.[1] UMODL1-AS1 is significantly associated with ER and triple negative status.[1]
Labs working on this lncRNA
- Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA. [1]
